Stock GPCR STRUCTURE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Structure Therapeutics Inc.

Equities

GPCR

US86366E1064

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
37.23 USD -1.43% Intraday chart for Structure Therapeutics Inc. -6.92% -8.66%
Jun. 27 Structure Therapeutics Inc. Appoints Ted W. Love as to the Audit Committee CI
Jun. 07 Structure Therapeutics Closes $547.4 Million Offering MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
GL
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
GL
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
GL
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
GL
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
GL
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
AQ
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
GL
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
GL
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
AQ
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
GL
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
GL
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
AQ
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
GL
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
AQ
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
GL
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
GL
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
AQ
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
GL
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
AQ
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GPCR Stock
  4. News Structure Therapeutics Inc.
  5. Press Releases